<DOC>
	<DOCNO>NCT00471289</DOCNO>
	<brief_summary>The purpose study investigate performance paclitaxel-coated balloon expandable stainless steel coronary stent treatment infrapopliteal stenosis occlusion patient critical limb ischemia compare percutaneous transluminal balloon angioplasty ( PTA ) .</brief_summary>
	<brief_title>PTA Drug Eluting Stents Infrapopliteal Lesions Critical Limb Ischemia</brief_title>
	<detailed_description>Critical limb ischemia ( CLI ) serious condition become common western world due grow percentage elderly population rise incidence diabetes . In 40 % patient stenosis occlusion artery level knee present . Restoration blood flow imperative allow pain relief tissue heal . Without revascularization patient CLI risk limb loss potentially fatal complication sepsis . In patient treat percutaneous transluminal balloon angioplasty ( PTA ) significant restenosis find approximately 50 % 6 month . In interventional cardiology significant reduction restenosis rate coronary artery find use drug elute stent ( DES ) , include paclitaxel elute stent ( TAXUS , Boston Scientific ) . DES locally deliver drug ( e.g . paclitaxel ) interfere restenosis process . Using DES treat knee ( infrapopliteal ) arterial lesion patient CLI may improve patency clinical outcome . Comparison : Treatment knee arterial lesion patient CLI PTA DES compare PTA .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent Age &gt; 18 year If female patient child bear potential , patient may pregnant study entry must utilize reliable birth control duration participation study Patient willing able comply specify followup evaluation Critical Limb Ischaemia , Fontaine stage III ( ischaemic rest pain ) IV ( ischaemic ulcer gangrene ) Rutherford category 4 ( ischaemic rest pain ) , 5 ( minor tissue loss ) 6 ( major tissue loss ) Stenotic ( &gt; 50 % luminal loss ) occlude infrapopliteal artery , include tibiofibular trunk , anterior tibial artery , posterior tibial artery peroneal artery , lesion length â‰¤ 60 mm Artery treat diameter tham equal 2mm less equal 4mm Patent common iliac , external iliac , superficial femoral popliteal artery ipsilateral side prior randomisation , possibly treatment session At least one patent crural ( anterior tibial , posterior tibial peroneal ) artery expect unobstructed runoff ankle level treatment Acute limb ischaemia Subacute limb ischaemia require thrombolysis first treatment modality Active bleeding bleeding diathesis Recent ( less 3 month ) hemorrhagic stroke CNS abnormality increase risk haemorrhage , intracranial neoplasm , arteriovenous malformation , intracranial aneurysm aneurysm repair Gastrointestinal genitourinary bleed clinical significance within previous 6 week treatment Aneurysm common femoral , superficial femoral popliteal artery ipsilateral side Revascularization involve limb within 30 day prior index procedure plan revascularization limb within 30 day index procedure Previous implant stent index site Life expectancy le 6 month factor make clinical followup difficult Known allergy acetylsalicylic acid ( aspirin ) , clopidogrel , heparin paclitaxel Known allergy contrast medium Known heparin induce thrombocytopenia ( HIT type 2 ) Patient unable unwilling tolerate anticoagulant , antiplatelet therapy contrast medium Creatinine clearance &lt; 20 ml/min ( derive CockcroftGault MDRD formula ) unless patient hemodialysis Aneurysm common femoral , superficial femoral popliteal artery ipsilateral side Severely calcify lesion expect resistance stenting Poor inflow due ipsilateral stenosis occlusion iliac femoropopliteal artery treat session Significant vessel tortuosity parameter prohibit access lesion and/or delivery stent Patients without ( expect ) distal runoff index site Previous implant stent index site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Stents</keyword>
	<keyword>Drug Eluting Stents</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>PAD</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>TAXUS</keyword>
	<keyword>Infrapopliteal</keyword>
	<keyword>Infragenicular</keyword>
	<keyword>Interventional Radiology</keyword>
	<keyword>CLI</keyword>
	<keyword>DES</keyword>
</DOC>